[{"id":"2fc6e26e-1c88-4f2c-acb5-aa1c3f319425","acronym":"","url":"https://clinicaltrials.gov/study/NCT05304962","created_at":"2022-03-31T17:52:56.793Z","updated_at":"2024-07-02T16:35:33.621Z","phase":"Phase 1","brief_title":"First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer","source_id_and_acronym":"NCT05304962","lead_sponsor":"Regor Pharmaceuticals Inc.","biomarkers":" HER-2 • PIK3CA • CDK4","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG6794"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 08/28/2024","study_completion_date":" 08/28/2024","last_update_posted":"2023-10-13"}]